Thermo Fisher Scientific Introduces the Gibco CTS Compleo Fill and Finish System

Thermo Fisher Scientific Inc. has globally launched the Gibco CTS Compleo Fill and Finish System, an automated, functionally closed solution designed to streamline formulation and filling in cell therapy manufacturing.

Since cell therapies often begin with patient-derived cells, manufacturing workflows must accommodate variability in cell count, concentration, and viability. As more therapies move toward commercialization, manufacturers want to reduce manual intervention and improve operational efficiency while maintaining strict requirements for sterility, dose accuracy, and product consistency.

Formulation and filling have been traditionally performed using manual methods that require careful handling of fragile cells in small volumes, introducing variability and contamination risk. The CTS Compleo system offers a compact, automated, functionally closed solution for formulation and filling, helping reduce manual intervention and supporting consistent batch-to-batch performance, bigwigs claim.

“We’re excited to bring forward a solution that addresses one of the biggest bottlenecks in cell therapy manufacturing, manual fill and finish,” said Tiffani Manolis, vice president and general manager, cell biology, Thermo Fisher Scientific. “By combining automation with a functionally closed design, the Gibco CTS Compleo system has the ability to streamline workflows, improve consistency, and help customers accelerate the delivery of life-changing therapies to patients.”

Early collaborators are experiencing the benefits from using the advanced technology in the CTS Compleo system to reduce variability and streamline cell therapy manufacturing.

“As we continue advancing our cell therapy programs, scalable and automated closed-system manufacturing solutions are a key priority,” said Ryan Zapata, senior process engineer at Arsenal Biosciences Inc. “The Compleo system offers a platform for closed formulation and fill that can be easily integrated into existing autologous cell therapy processes. The intuitive protocol builder software allows for flexibility and rapid iteration in the development environment, enabling use across programs.”

The CTS Compleo system is part of the Gibco Cell Therapy Systems (CTS) portfolio, which supports cell therapy manufacturers with instruments, consumables, and software, GMP-manufactured media and reagents, and viral vector systems. Together, these solutions, along with the Gibco PeproGMP growth factors and cytokines, help enable GMP-compliant, closed-system manufacturing and allow for physical and digital integration across the workflow.

Thermo Fisher also provides services to implement the CTS Compleo system, including installation, application and process development support, and global service coverage.

Thermo Fisher Scientific Inc. considers itself the world leader in serving science, with annual revenue of more than $40 billion. Whether its customers are accelerating life sciences research, solving complex analytical challenges, increasing laboratory productivity, improving patient health through diagnostics or the development and manufacture of life-changing therapies, Thermo Fisher Scientific supports them. Its global team delivers a combination of technologies, purchasing convenience, and pharmaceutical services through various brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD.